Plain-English translation of NCT07396376 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called ELU42, a topical spray designed to help diabetic foot ulcers heal by improving the body's natural wound-healing process. Researchers will apply the medication directly to your foot ulcer over six weeks and monitor how well it works and whether it's safe. This is an early-stage study with a small group of patients to understand if this treatment is promising.
Diabetic foot ulcers are a serious complication of diabetes that can take a long time to heal and may lead to infection or amputation. This trial exists to see whether this new medication can speed up healing and reduce the burden of this common and painful condition.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic regularly over approximately six weeks to have the medication spray applied to your foot ulcer and to have your wound measured and photographed to track healing. The study team will also do blood tests and heart monitoring to make sure the treatment is safe. If your ulcer heals completely but then reopens, you may restart treatment for another six-week course.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States